Clinical trial
The Effect of Adjunctive Intravitreal Aflibercept for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy
NCT05478967 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Adjunctive Intravitreal Aflibercept for Preventing Postvitrectomy Hemorrhage in Proliferative Diabetic Retinopathy
- Lead sponsor
- Peking University People's Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- August 8, 2019
- Completion date
- February 20, 2021
- Enrollment
- 154 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
proliferative diabetic retinopathy